• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肿瘤浸润性 T 淋巴细胞治疗后外源人类疱疹病毒 6 再感染。

Exogenous human herpesvirus 6 reinfection after tumor-infiltrating T-lymphocyte therapy.

机构信息

Laboratory of Virology, University Hospital of Grenoble, Grenoble, France; Irkutsk State Medical University, Ministry of Health of Russia, Irkutsk, Russia.

Dermatology Unit, Univ. Grenoble Alpes, IAB, University Hospital of Grenoble, Grenoble, France.

出版信息

Cytotherapy. 2018 Apr;20(4):521-523. doi: 10.1016/j.jcyt.2017.12.006. Epub 2018 Feb 9.

DOI:10.1016/j.jcyt.2017.12.006
PMID:29434005
Abstract

Exogenous human herpes virus 6 (HHV-6) reinfection has never been reported in patients receiving tumor-infiltrating T lymphocytes therapy. We report an unusual case of HHV-6 infection following infusion of HHV-6 infected autologous T lymphocytes. HHV-6 infection could interfere with the tumor antigen immune recognition and the efficacy of immunotherapy.

摘要

接受过肿瘤浸润性 T 淋巴细胞治疗的患者从未报告过外源性人类疱疹病毒 6（HHV-6）再感染。我们报告了一例在输注 HHV-6 感染的自体 T 淋巴细胞后发生 HHV-6 感染的不寻常病例。HHV-6 感染可能会干扰肿瘤抗原的免疫识别和免疫疗法的疗效。

相似文献

1
Exogenous human herpesvirus 6 reinfection after tumor-infiltrating T-lymphocyte therapy.肿瘤浸润性 T 淋巴细胞治疗后外源人类疱疹病毒 6 再感染。
Cytotherapy. 2018 Apr;20(4):521-523. doi: 10.1016/j.jcyt.2017.12.006. Epub 2018 Feb 9.
2
Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.随机 II 期试验：在转移性黑色素瘤患者中，采用淋巴细胞清除联合肿瘤浸润淋巴细胞过继转移治疗，联合或不联合树突状细胞疫苗接种。
J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2021-002449.
3
Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model.过继性T细胞转移的临床反应可以在自体免疫人源化小鼠模型中进行模拟。
Nat Commun. 2017 Sep 27;8(1):707. doi: 10.1038/s41467-017-00786-z.
4
Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma.利用 T 细胞激活信号 1、2 和 3 扩增肿瘤浸润淋巴细胞（TIL）：优于单独使用白细胞介素-2 治疗皮肤和葡萄膜黑色素瘤。
J Immunother. 2018 Nov/Dec;41(9):399-405. doi: 10.1097/CJI.0000000000000230.
5
Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases.肿瘤浸润淋巴细胞过继细胞转移治疗伴或不伴脑转移的转移性黑色素瘤患者的结局。
J Immunother. 2018 Jun;41(5):241-247. doi: 10.1097/CJI.0000000000000223.
6
Is antigen specificity the key to efficient adoptive T-cell therapy?抗原特异性是否是高效过继性 T 细胞治疗的关键？
Immunotherapy. 2011 Apr;3(4):495-505. doi: 10.2217/imt.11.16.
7
Predictors of tumor-infiltrating lymphocyte efficacy in melanoma.黑色素瘤中肿瘤浸润淋巴细胞疗效的预测因素。
Immunotherapy. 2016;8(1):35-43. doi: 10.2217/imt.15.99. Epub 2015 Dec 10.
8
Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma.在已切除的III期和IV期黑色素瘤患者中采用肿瘤浸润淋巴细胞和白细胞介素-2进行辅助免疫治疗。
J Immunother. 2003 Mar-Apr;26(2):156-62. doi: 10.1097/00002371-200303000-00008.
9
T cell triumph. Immunotherapy may have finally turned a corner.
Sci Am. 2003 Feb;288(2):12-3.
10
Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.转移性黑色素瘤患者在进行淋巴细胞清除化疗方案后，经最少培养或筛选的自体肿瘤浸润淋巴细胞。
J Immunother. 2009 May;32(4):415-23. doi: 10.1097/CJI.0b013e31819c8bda.